Jyllinge, Denmark

Peter Mouritzen

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2012-2021

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Peter Mouritzen

Introduction

Peter Mouritzen is a notable inventor based in Jyllinge, Denmark. He has made significant contributions to the field of nucleic acid analysis, holding a total of six patents. His work focuses on developing methods and tools for detecting and classifying nucleic acids, which are crucial for various applications in biotechnology and medicine.

Latest Patents

Mouritzen's latest patents include innovative technologies such as probes, libraries, and kits for the analysis of mixtures of nucleic acids. This invention relates to nucleic acid probes, libraries, and kits designed for detecting, classifying, or quantifying components in complex mixtures, such as transcriptomes. Additionally, he has developed a microRNA-based method for the early detection of prostate cancer in urine samples. This method assesses the risk of prostate cancer by measuring the expression levels of specific microRNAs in patient samples.

Career Highlights

Throughout his career, Mouritzen has worked with prominent companies in the biotechnology sector, including Qiagen GmbH and Exiqon A/S. His experience in these organizations has contributed to his expertise in nucleic acid technologies and their applications in medical diagnostics.

Collaborations

Mouritzen has collaborated with notable colleagues such as Søren Morgenthaler Echwald and Lars Kongsbak. These partnerships have further enhanced his research and development efforts in the field of nucleic acids.

Conclusion

Peter Mouritzen's innovative work in nucleic acid analysis has led to significant advancements in biotechnology and medical diagnostics. His contributions continue to impact the field positively, showcasing the importance of innovation in addressing complex biological challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…